These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 26149041)

  • 21. Platelet function testing: dead or alive.
    Helten C; Naguib D; Dannenberg L; Pöhl M; Ayhan A; Hohlfeld T; Levkau B; Kelm M; Zeus T; Polzin A
    J Thromb Haemost; 2018 May; 16(5):984-986. PubMed ID: 29512292
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Platelet function testing guided antiplatelet therapy reduces cardiovascular events in Chinese patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: The PATROL study.
    You J; Li H; Guo W; Li J; Gao L; Wang Y; Geng L; Wang X; Wan Q; Zhang Q
    Catheter Cardiovasc Interv; 2020 Feb; 95 Suppl 1():598-605. PubMed ID: 31957972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel anti-platelet agents: focus on thrombin receptor antagonists.
    de Souza Brito F; Tricoci P
    J Cardiovasc Transl Res; 2013 Jun; 6(3):415-24. PubMed ID: 23435863
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents).
    Kirtane AJ; Parikh PB; Stuckey TD; Xu K; Witzenbichler B; Weisz G; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Brodie BR; Mazzaferri EL; Parvataneni R; Maehara A; Généreux P; Mehran R; Stone GW
    JACC Cardiovasc Interv; 2015 Dec; 8(15):1978-1987. PubMed ID: 26738669
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes.
    Braunwald E; Angiolillo D; Bates E; Berger PB; Bhatt D; Cannon CP; Furman MI; Gurbel P; Michelson AD; Peterson E; Wiviott S
    Clin Cardiol; 2008 Mar; 31(3 Suppl 1):I2-9. PubMed ID: 18481818
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) Trial.
    Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Gori T; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Thalmeier A; Löw A; Holdt L; Teupser D; Ince H; Felix SB; Parma R; Malek L; Horstkotte J; Baylacher M; Schwinger R; Rieber J; Mudra H; Hausleiter J; Huber K; Neumann FJ; Koltowski L; Huczek Z; Mehilli J; Massberg S;
    Thromb Haemost; 2017 Jan; 117(1):188-195. PubMed ID: 27652610
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiplatelet therapy in acute coronary syndromes.
    Grove EL; Würtz M; Thomas MR; Kristensen SD
    Expert Opin Pharmacother; 2015; 16(14):2133-47. PubMed ID: 26293612
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiplatelet agents in hemodialysis.
    Migliori M; Cantaluppi V; Scatena A; Panichi V
    J Nephrol; 2017 Jun; 30(3):373-383. PubMed ID: 27928736
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacological inhibition of platelet reactivity. Clinical and pharmacodynamic effects.
    Vallés J; Moscardo A; Madrid I; Santos MT
    Curr Vasc Pharmacol; 2013 Jul; 11(4):431-47. PubMed ID: 23905638
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging oral antiplatelet therapies for acute coronary syndromes.
    Pollack CV
    Hosp Pract (1995); 2010 Nov; 38(4):29-37. PubMed ID: 21068524
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.
    Dyke CM
    Am Heart J; 1999 Oct; 138(4 Pt 2):307-16. PubMed ID: 10502236
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Platelet receptors as therapeutic targets: Past, present and future.
    Jamasbi J; Ayabe K; Goto S; Nieswandt B; Peter K; Siess W
    Thromb Haemost; 2017 Jun; 117(7):1249-1257. PubMed ID: 28597906
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
    Holmes LE; Gupta R; Rajendran S; Luu J; French JK; Juergens CP
    Cardiovasc Ther; 2016 Oct; 34(5):330-6. PubMed ID: 27327862
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Current antiplatelet agents, new inhibitors and therapeutic targets].
    El Alaoui MZ; Guy A; Khalki L; Limami Y; Benomar A; Zaid N; Cherrah Y; Mekhfi H; Cadi R; Zaid Y
    Med Sci (Paris); 2020 Apr; 36(4):348-357. PubMed ID: 32356711
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Platelet function and antiplatelet therapy in cardiovascular disease: implications of genetic polymorphisms.
    Shanker J; Gasparyan AY; Kitas GD; Kakkar VV
    Curr Vasc Pharmacol; 2011 Jul; 9(4):479-89. PubMed ID: 21314637
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of P2Y12 inhibitors according to diabetes, age, gender, body mass index and body weight: systematic review and meta-analyses of randomized clinical trials.
    Zaccardi F; Pitocco D; Willeit P; Laukkanen JA
    Atherosclerosis; 2015 Jun; 240(2):439-45. PubMed ID: 25897998
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evolving role of platelet function testing in coronary artery interventions.
    Sharma RK; Voelker DJ; Sharma R; Reddy HK; Dod H; Marsh JD
    Vasc Health Risk Manag; 2012; 8():65-75. PubMed ID: 22371653
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proteomic signatures of antiplatelet drugs: new approaches to exploring drug effects.
    Marcone S; Dervin F; Fitzgerald DJ
    J Thromb Haemost; 2015 Jun; 13 Suppl 1():S323-31. PubMed ID: 26149042
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Vandvik PO; Lincoff AM; Gore JM; Gutterman DD; Sonnenberg FA; Alonso-Coello P; Akl EA; Lansberg MG; Guyatt GH; Spencer FA
    Chest; 2012 Feb; 141(2 Suppl):e637S-e668S. PubMed ID: 22315274
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial.
    Li Y; Jing Q; Wang B; Wang X; Li J; Qiao S; Chen S; Angiolillo DJ; Han Y
    Am Heart J; 2020 Oct; 228():1-7. PubMed ID: 32739652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.